🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#NEWS: Results from phase 3 studies of our investigational treatment for adults with #MultipleSclerosis were published in NEJM and presented during a plenary session at this year’s American Academy of Neurology’s Annual Meeting #AANAM Learn more ⬇️

Before Chrissy Teigen’s son Miles was unexpectedly diagnosed with #type1diabetes, her family knew nothing about the disease. Now, she’s joining the Screen For Type 1 movement to build awareness for T1D screening. Learn more ⬇️

Today, the U.S. FDA approved our medicine for #ChronicSpontaneousUrticaria (CSU) for certain patients aged 12 years and older, marking the first new targeted therapy for people with this inflammatory skin disease in more than a decade. Read more about the news 👇 CC: Regeneron

Our first quarter 2025 results are now available. Read the press release. ⤵️ #SanofiResults $SAN $SNY

#NEWS: New data at #ATS2025 will showcase our scientific leadership and breadth of innovation in chronic inflammatory respiratory conditions, including #COPD and #asthma. Read about our data ⬇️ CC: Regeneron

Uncontrolled asthma shouldn’t be a barrier to enjoying life. This #WorldAsthmaDay, understand the symptoms of uncontrolled asthma and talk to a healthcare provider.

What’s one hidden contributor to severe asthma symptoms? Mucus plugs. By better understanding the connection between mucus plugs and asthma symptoms, we hope to pave the way for improved care for this respiratory disease. Learn more.

Unveiling #SanofiAtMorristown—our new innovative workspace in NJ. Our CEO Paul Hudson joins local leaders to open this state-of-the-art hub where scientific innovation and collaboration fuel tomorrow’s breakthroughs 🏢✨ Learn more ⬇️

#NEWS: The U.S. FDA has expanded the indication for use of our vaccination for protection against meningococcal #meningitis to infants aged six weeks and older. Read more ⬇️

#NEWS: First real-world comparison of respiratory syncytial virus (#RSV) immunization programs for infants to be presented at #ESPID2025. Read more ⬇️

#News: The U.S. FDA has granted Orphan Drug Designation to our novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of #SickleCellDisease. Read more about the potential of this novel approach ⬇️

#NEWS: New data at #ASCO25 published in Journal of Clinical Oncology analyzed the potential of an investigational delivery method to administer our investigational subcutaneous #MultipleMyeloma combination therapy. Learn more ⬇️

#News: At ISTH 2025, we’re presenting new data highlighting our commitment to evolving patient expectations and exploring therapeutic options for #RareBloodDisorders. Learn more about our ongoing work in immune thrombocytopenia (#ITP) and #hemophilia ⬇️

At #RAD2025, we shared new phase 4 data in people with skin of color and #AtopicDermatitis. Explore the results we presented with Regeneron ⬇️

#NEWS: Respiratory syncytial virus (#RSV) prevention is being scaled in ambition to help protect every U.S. baby — again in 2025. Because when #science works, we make sure it can reach everyone. Learn more ⬇️

Our treatment for #BullousPemphigoid (BP) is now approved by the U.S. FDA. This approval helps close a long-standing gap in care for adults with this chronic, relapsing skin condition. CC: Regeneron

#NEWS: Two different AI/ML based models accepted as late-breakers were presented at #ADA2025, showing potential to detect type 1 diabetes early. Learn more: spkl.io/6017A6T01

The U.S. FDA has granted Orphan Drug Designation to our investigational treatment for antibody-mediated rejection (AMR) in solid organ transplantation, reinforcing our commitment to addressing critical unmet needs in #Transplant medicine. Learn more ⬇️

Wrapping up a great week at the American Diabetes Association - DiabetesPro Conference in Chicago, IL! Thanks for another great year full of connection & collaboration with the diabetes community. Check out a few pictures of our team on the ground at #ADA2025 below.

Through our newly launched Health Futures Solution Fund, we're awarding grants to 13 nonprofits across Massachusetts tackling food insecurity, housing, and more. 🌍 Learn more: spkl.io/6016A6f8M #HealthyFutures #SocialImpact #CommunityPartnerships